A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback